At Oncopeptides, we are advancing therapies for difficult-to-treat hematological diseases.
With established North America operations based in Mountain View, California, Oncopeptides is poised for continued growth in this global hub of biotech pioneers, scientific exploration and technological innovation.
Oncopeptides’ lead candidate, melflufen, is an investigational, first-in-class, peptide-drug conjugate that rapidly delivers a cytotoxic payload directly to tumor cells and is initially being developed in advanced multiple myeloma. Melflufen is an investigational drug and is not approved for commercial use.
Please visit the Contact Us page to contact Oncopeptides directly. During this exciting period of growth, Oncopeptides is actively seeking bright, energetic candidates with experience working in health care or biopharmaceutical to join the team. Learn more and submit a resume at the Careers page.
Oncopeptides North America is a subsidiary of Oncopeptides AB (Nasdaq Stockholm: ONCO), which is headquartered in Stockholm, Sweden.